-DOCSTART- -X- O
Non-alcoholic -X- _ B-Patient
fatty -X- _ I-Patient
liver -X- _ I-Patient
disease -X- _ I-Patient
( -X- _ I-Patient
NAFLD -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
currently -X- _ O
considered -X- _ O
an -X- _ O
important -X- _ O
component -X- _ O
of -X- _ O
metabolic -X- _ O
syndrome -X- _ O
( -X- _ O
MetS -X- _ O
) -X- _ O
. -X- _ O
The -X- _ O
spectrum -X- _ O
of -X- _ O
NAFLD -X- _ O
includes -X- _ O
conditions -X- _ O
that -X- _ O
range -X- _ O
from -X- _ O
simple -X- _ O
hepatic -X- _ O
steatosis -X- _ O
to -X- _ O
non-alcoholic -X- _ O
steatohepatitis. -X- _ O
NAFLD -X- _ O
is -X- _ O
correlated -X- _ O
with -X- _ O
liver-related -X- _ O
death -X- _ O
and -X- _ O
is -X- _ O
predicted -X- _ O
to -X- _ O
be -X- _ O
the -X- _ O
most -X- _ O
frequent -X- _ O
indication -X- _ O
for -X- _ O
liver -X- _ O
transplantation -X- _ O
by -X- _ O
2030. -X- _ O
Insulin -X- _ O
resistance -X- _ O
is -X- _ O
directly -X- _ O
correlated -X- _ O
to -X- _ O
the -X- _ O
central -X- _ O
mechanisms -X- _ O
of -X- _ O
hepatic -X- _ O
steatosis -X- _ O
in -X- _ O
NAFLD -X- _ B-Patient
patients -X- _ I-Patient
, -X- _ O
which -X- _ O
is -X- _ O
strongly -X- _ O
correlated -X- _ O
to -X- _ O
the -X- _ O
imbalance -X- _ O
of -X- _ O
the -X- _ O
renin–angiotensin -X- _ O
system -X- _ O
, -X- _ O
that -X- _ O
is -X- _ O
involved -X- _ O
in -X- _ O
lipid -X- _ O
and -X- _ O
glucose -X- _ O
metabolism. -X- _ O
Among -X- _ O
the -X- _ O
emerging -X- _ O
treatment -X- _ O
approaches -X- _ O
for -X- _ O
NAFLD -X- _ O
is -X- _ O
the -X- _ O
antihypertensive -X- _ B-Intervention
agent -X- _ I-Intervention
telmisartan -X- _ I-Intervention
, -X- _ O
which -X- _ O
has -X- _ O
positive -X- _ B-Outcome
effects -X- _ I-Outcome
on -X- _ I-Outcome
liver -X- _ I-Outcome
, -X- _ I-Outcome
lipid -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
glucose -X- _ I-Outcome
metabolism -X- _ I-Outcome
, -X- _ I-Outcome
especially -X- _ I-Outcome
through -X- _ I-Outcome
its -X- _ I-Outcome
action -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
renin–angiotensin -X- _ I-Outcome
system -X- _ I-Outcome
, -X- _ I-Outcome
by -X- _ I-Outcome
blocking -X- _ I-Outcome
the -X- _ I-Outcome
ACE -X- _ I-Outcome
/ -X- _ I-Outcome
AngII -X- _ I-Outcome
/ -X- _ I-Outcome
AT1 -X- _ I-Outcome
axis -X- _ I-Outcome
and -X- _ I-Outcome
increasing -X- _ I-Outcome
ACE2 -X- _ I-Outcome
/ -X- _ I-Outcome
Ang -X- _ I-Outcome
( -X- _ I-Outcome
1–7 -X- _ I-Outcome
) -X- _ I-Outcome
/ -X- _ I-Outcome
Mas -X- _ I-Outcome
axis -X- _ I-Outcome
activation. -X- _ I-Outcome
However -X- _ O
, -X- _ O
treatment -X- _ O
with -X- _ O
this -X- _ O
drug -X- _ O
is -X- _ O
only -X- _ B-Outcome
recommended -X- _ I-Outcome
for -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
established -X- _ I-Outcome
indication -X- _ I-Outcome
for -X- _ I-Outcome
anti-hypertensive -X- _ I-Outcome
therapy. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
an -X- _ O
increased -X- _ O
need -X- _ O
for -X- _ O
large -X- _ O
randomized -X- _ O
controlled -X- _ O
trials -X- _ O
with -X- _ O
the -X- _ O
aim -X- _ O
of -X- _ O
elucidating -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
telmisartan -X- _ B-Intervention
on -X- _ O
liver -X- _ O
disease -X- _ O
, -X- _ O
especially -X- _ O
NAFLD. -X- _ O
From -X- _ O
this -X- _ O
perspective -X- _ O
, -X- _ O
the -X- _ O
present -X- _ O
review -X- _ O
aims -X- _ O
to -X- _ O
provide -X- _ O
a -X- _ O
brief -X- _ O
examination -X- _ O
of -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
NAFLD -X- _ O
/ -X- _ O
NASH -X- _ O
and -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
telmisartan -X- _ O
on -X- _ O
preventing -X- _ O
liver -X- _ O
disorders -X- _ O
and -X- _ O
thus -X- _ O
to -X- _ O
improve -X- _ O
the -X- _ O
discussion -X- _ O
on -X- _ O
potential -X- _ O
therapies -X- _ O
. -X- _ O

